Life-extending cancer drugs to be axed by NHS NHS England de-lists costly Kadcyla drug, among 16 others, in wake of ‘overspent’ Cancer Drugs Fund.
New and costly cancer drugs developed to extend the lives of patients are expected to be axed on Friday from an NHS list. Among the drugs NHS England is expected to “de-list” from the Cancer Drugs Fund is Kadcyla, which holds the record as the most expensive cancer drug brought to market, costing £90,000 annually per patient.
Kadcyla, made by Roche, was rejected from general NHS use by the National Institute for Health and Care Excellence (Nice), the body that assesses new medicines for their cost-effectiveness. Continue reading... The Guardian
No comments:
Post a Comment